The Amyloidosis Channel on VJHemOnc is an independent medical education platform, supported with funding from Prothena (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ISA 2020 | Auto-HSCT in AL amyloidosis
Autologous stem cell transplant (ASCT) has been utilized in the management of immunoglobulin light chain (AL) amyloidosis for several decades. The use of ASCT has been associated with high rates of hematologic response and improvement in organ function. However, novel agents have challenged the use of ASCT. Eli Muchtar, MD, Mayo Clinic, Rochester, MN, discusses the burning questions in the use of ASCT in AL amyloidosis. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
